Article
Immunology
Song Guan, Shufeng Zhang, Kai Ren, Xingyue Li, Xue Li, Lujun Zhao
Summary: This study retrospectively analyzed the efficacy and safety of induction chemoimmunotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy (CRT). The study found that induction chemoimmunotherapy improved progression-free survival and showed better treatment response and survival outcomes in patients receiving concurrent chemoradiotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, Yiduo Zhang
Summary: Durvalumab was found to be cost-effective compared with cCRT alone in patients with unresectable stage III NSCLC in a US healthcare setting, with incremental cost-effectiveness ratios indicating it was below the willingness-to-pay threshold. Sensitivity and scenario analyses highlighted variables affecting the model, but overall the adoption of Durvalumab following cCRT as the new standard of care was supported.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Immunology
Linfang Wu, Daquan Wang, Yanhua Chen, Mingmin Qian, Xin Xu, Tao Zhang, Nan Bi, Luhua Wang
Summary: This study tracked the dynamics of IDO1 activity in stage III non-small cell lung cancer patients who received radiotherapy and found that a favorable change in IDO1 activity was associated with superior overall survival, progression-free survival, and local control. IDO1 activity holds promise as a prognostic biomarker for stage III NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Francesco Cortiula, Dirk De Ruysscher, Michelle Steens, Robin Wijsman, Anthonie van der Wekken, Martina Alberti, Lizza E. L. Hendriks
Summary: Adjuvant durvalumab is the standard treatment for stage III unresectable non-small cell lung cancer (NSCLC) patients without progression after chemo-radiation. Patients with EGFR mutations and ALK rearrangements do not benefit from durvalumab. This retrospective study showed that patients with uncommon driver genomic alterations (dGA), including KRAS mutations, had a meaningful survival benefit from adjuvant durvalumab.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jessica A. Hellyer, Jacqueline Aredo, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee
Summary: This retrospective analysis of patients with unresectable stage III NSCLC treated with consolidation durvalumab identified a shorter disease-free survival in patients with ERBB2/EGFR mutations. Further prospective studies are needed to evaluate this finding in the future.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Marina C. Garassino, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, Talal Mansy, Diego Cortinovis, Maria R. Migliorino, Angelo Delmonte, Jose Garcia Sanchez, Luis Enrique Chara Velarde, Reyes Bernabe, Luis Paz-Ares, Ignacio Diaz Perez, Nataliya Trunova, Kayhan Foroutanpour, Corinne Faivre-Finn
Summary: The study included 117 patients with advanced unresectable stage III NSCLC, showing that durvalumab after sequential CRT has a comparable safety profile to durvalumab after concurrent CRT and has promising preliminary efficacy in a frailer population.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Medicine, General & Internal
Abed Agbarya, Walid Shalata, Alfredo Addeo, Andriani Charpidou, Kristof Cuppens, Odd Terje Brustugun, Mirjana Rajer, Marco Jakopovic, Mihai Marinca, Adam Pluzanski, Jeroen Hiltermann, Antonio Araujo
Summary: This study investigated the strategies and management of locally advanced unresectable stage III non-small-cell lung cancer (NSCLC) in 11 different countries. The study found significant heterogeneity in real-world practices, highlighting the need for standardized evidence-based decisions.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Chiara Catania, Gaia Piperno, Alessandro Russo, Carlo Greco, Francesco Agustoni, Vieri Scotti, Claudia Proto, Claudia Sangalli, Fabiola Patani, Anna Santacaterina, Marzia Di Pietro Paolo, Benedetta Agresti, Andrea Riccardo Filippi, Sara Ramella
Summary: The treatment of stage III non-small cell lung cancer (NSCLC) has always been controversial and challenging. The results of the PACIFIC trial have provided a new therapeutic path for patients who are not eligible for surgery, leading to a significant prognostic advantage. However, the use of consolidative immunotherapy after chemoradiotherapy is still debated in certain clinically-relevant situations.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Review
Oncology
Yuchen Li, Rosalyn Anne Juergens, Christian Finley, Anand Swaminath
Summary: For the past two decades, treatment options for stage III NSCLC patients have been limited. However, in the past five years, there have been innovations in biomarker testing, novel therapeutics, precision surgery, and radiotherapy, leading to more personalized treatment options. This review article focuses on completed and ongoing initiatives for the treatment of stage III NSCLC patients.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Francesco Passiglia, Gianmarco Leone, Emanuela Olmetto, Marco Donatello Delcuratolo, Fabrizio Tabbo, Maria Lucia Reale, Valentina Bertaglia, Lorena Consito, Paolo Bironzo, Enrica Capelletto, Silvia Novello
Summary: The PACIFIC trial has established durvalumab consolidation as the new standard of care for stage III unresectable NSCLC, with significant improvements in long-term survival. Ongoing clinical trials are exploring intensified immune-checkpoint inhibition regimens to enhance therapeutic benefits for this population, while personalized approaches and effective treatments in the post-durvalumab progression setting remain areas of active research and debate in clinical lung cancer research.
Article
Oncology
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia
Summary: The PACIFIC trial showed that durvalumab improves PFS and OS in Stage III NSCLC patients, regardless of their response to prior CRT. However, in some subgroups, such as patients who received induction chemotherapy, the impact of durvalumab on OS may be limited.
Article
Oncology
Cheol-Kyu Park, Hyung-Joo Oh, Young-Chul Kim, Yong-Hyub Kim, Sung-Ja Ahn, Won Gi Jeong, Jeong Yeop Lee, Jae Cheol Lee, Chang Min Choi, Wonjun Ji, Si Yeol Song, Juwhan Choi, Sung Yong Lee, Hakyoung Kim, Shin Yup Lee, Jongmoo Park, Seong Hoon Yoon, Ji Hyeon Joo, In-Jae Oh
Summary: This study aimed to investigate the efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC. The results showed that durvalumab could prolong progression-free survival (rwPFS) and overall survival, but could also cause radiation pneumonitis and immune-related adverse events.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Adrien Holzgreve, Julian Taugner, Lukas Kaesmann, Philipp Mueller, Amanda Tufman, Niels Reinmuth, Minglun Li, Michael Winkelmann, Lena M. Unterrainer, Alexander E. Nieto, Peter Bartenstein, Wolfgang G. Kunz, Jens Ricke, Claus Belka, Chukwuka Eze, Marcus Unterrainer, Farkhad Manapov
Summary: In patients with unresectable stage III NSCLC, durvalumab maintenance treatment after CRT leads to diverging tumoral metabolic changes and increases splenic metabolism compared to patients undergoing CRT alone. The proportion of findings suggestive of irAE is also higher in CRT-IO patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Jarushka Naidoo, Scott Antonia, Yi-Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann, Michael Newton, Corinne Faivre-Finn
Summary: This study examined the efficacy of immunotherapy in patients with EGFR-mutant NSCLC. The results showed that durvalumab had similar PFS and OS compared to placebo, but due to small sample size and lack of prospective studies, further research is needed to determine the optimal treatment for EGFR-mutant NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Wei Li, Li Wan
Summary: The cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC in the Chinese healthcare system was assessed. The results showed that sugemalimab consolidation therapy was not cost-effective without considering patient assistance program, but became a cost-effective option with the program.
